Azacitidine for the treatment of relapsed and refractory AML in older patients

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 124-130

  Itzykson, Raphael ^a   Thépot, Sylvain ^b   Berthon, Céline ^c   Delaunay, Jacques ^d   Bouscary, Didier ^e   Cluzeau, Thomas ^f   Turlure, Pascal ^g   Prébet, Thomas ^h   Dartigeas, Caroline ⁱ   Marolleau, Jean Pierre ^j   Recher, Christian ^k   Plantier, Isabelle ^l   Stamatoullas, Aspasia ^m   Devidas, Alain ⁿ   Taksin, Anne Laure ^o   Guièze, Romain ^p   Caillot, Denis ^q   Vey, Norbert ^h   Adès, Lionel ^a   Ifrah, Norbert ^r   Dombret, Hervé ^a   Fenaux, Pierre ^a   Gardin, Claude ^b   more..

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e Institut Paoli Calmettes ^*  (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ UNIVERSITY HOSPITAL OF TOURS   (France)

^j AMIENS UNIVERSITY HOSPITAL   (France)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

^l CENTRE HOSPITALIER DE ROUBAIX   (France)

^m CENTRE HENRI BECQUEREL   (France)

ⁿ Center Hospitalier Sud Francilien   (France)

^o LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^p UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^q DIJON UNIVERSITY HOSPITAL   (France)

^r ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Acute myeloid leukemia; Azacitidine; Induction failure; Relapse

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYTOGENETICS; DOSE RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SEPSIS; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; BLAST CRISIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLAST CRISIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84921438631     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.009     Document Type: Article

References (29)

1. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
2. Sarkozy C., Gardin C., Gachard N., et al. Outcome of older patients with acute myeloid leukemia in first relapse. Am J Hematol 2013, 88(9):758-764.
3. Faderl S., Wetzler M., Rizzieri D., et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol 2012, 30(20):2492-2499.
4. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
5. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28(4):562-569.
6. Thépot S., Itzykson R., Seegers V., et al. Azacitidine in untreated acute myeloid leukemia. A report on 149 patients. Am J Hematol 2014, 89(4):410-416.
7. van der Helm L.H., Veeger N.J., Kooy M., et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res 2013, 37(8):877-882.
8. Quintas-Cardama A., Ravandi F., Liu-Dumlao T., et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012, 120(24):4840-4845.
9. Walter R.B., Medeiros B.C., Gardner K.M., et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase 1/2 study. Haematologica 2013.
10. Raffoux E., Cras A., Recher C., et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1(1):34-42.
11. Ravandi F., Alattar M.L., Grunwald M.R., et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121(23):4655-4662.
12. Al-Ali H.K., Jaekel N., Junghanss C., et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012, 53(1):110-117.
13. Maurillo L., Venditti A., Spagnoli A., et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012, 118(4):1014-1022.
14. Pleyer L., Stauder R., Burgstaller S., et al. Azacitidine in patients with WHO-defined AML-results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 2013, 6(1):32.
15. Tawfik B., Sliesoraitis S., Lyerly S., et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol 2013.
16. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98(5):1312-1320.
17. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21(24):4642-4649.
18. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.
19. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15(4):361-387.
20. White I.R., Royston P., Wood A.M. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011, 30(4):377-399.
21. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26(29):4791-4797.
22. Ritchie E.K., Feldman E.J., Christos P.J., et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013, 54(9):2003-2007.
23. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27(11):1850-1856.
24. Estey E.H. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 2013, 27(9):1803-1812.
25. Falantes J.F., Calderon C., Marquez-Malaver F.J., et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 2013.
26. Itzykson R., Thepot S., Quesnel B., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(2):403-411.
27. Chevallier P., Labopin M., Turlure P., et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011, 25(6):939-944.
28. How J., Sykes J., Minden M.D., et al. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. Blood Cancer J 2013, 3:e116.
29. van der Helm L.H., Alhan C., Wijermans P.W., et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011, 155(5):599-606.